Immuron Ltd ADR IMRN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives
Emerging Growth Research Reports Continued Revenue Growth at Immuron
Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference
Travelan® Phase 2 Study Results Published
Immuron to launch PROIBS® in the United States
Immuron Reports FY26 Preliminary Results
Trading Information
- Previous Close Price
- $0.85
- Day Range
- $0.81–0.90
- 52-Week Range
- $0.68–1.99
- Bid/Ask
- $0.77 / $0.85
- Shares Outstanding
- 8.07M
- Market Cap
- $7.26M
- Volume/Avg
- 19,698 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.28
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 8
- Website
- https://www.immuron.com.au
Valuation
Metric | IMRN |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.95 |
Price/Sales | 1.28 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | IMRN |
|---|---|
Quick Ratio | 5.84 |
Current Ratio | 7.26 |
Interest Coverage | −261.74 |
Quick Ratio
IMRN
Profitability
Metric | IMRN |
|---|---|
Return on Assets (Normalized) | −27.78% |
Return on Equity (Normalized) | −33.04% |
Return on Invested Capital (Normalized) | −34.62% |
Return on Assets
IMRN
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|Nr@<!j@ | LOCK|N@hn | $131B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|Q>l??Ww | LOCK|p&$Rh | $95B | |||
| Moderna Inc MRNA | LOCK|fVm>ZZ? | LOCK|txR | $79B | |||
| argenx SE ADR ARGX | LOCK|H!Ylg#! | LOCK|&R | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|S<S$jQ | LOCK|Xv | $45B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|s$w?<SM | LOCK|X>!j# | $30B | |||
| Incyte Corp INCY | LOCK|WgFYyx | LOCK|Ymb | $23B | |||
| BioNTech SE ADR BNTX | LOCK|&<#SFr | LOCK|N#! | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|VmXf^<c | LOCK|Rk^#H | $19B | |||
| BridgeBio Pharma Inc BBIO | LOCK|<Vsh&P | LOCK|?fs | $15B |